HopeStage
Back to all studies
RecruitingNCT05958875

Earlier clozapine or usual care after initial treatment failure in schizophrenia

About this titleRead the official source — NCT05958875

Researchers are comparing Clozapine and Second-line Antipsychotics (treatment as usual) to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Medication studyAges 18–70Multiple countries
The study in practice

Understand this study

What is this study about?

Researchers are comparing Clozapine and Second-line Antipsychotics (treatment as usual) to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

Listed locations
Innsbruck and 12 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 1, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
418
Sponsor
Dr. Inge Winter
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom, Austria, Germany, ...
Age range
From 18 Years to 70 Years
Official registry ID
NCT05958875
Official title
Show the full official title

A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruitment & locations

Currently recruiting

Innsbruck, Austria · Augsburg, Germany · Bielefeld, Germany

10 more locations
  • Dortmund, Germany
  • Frankfurt am Main, Germany
  • Mainz, Germany
  • Münster, Germany
  • Brescia, Italy
  • Cagliari, Italy
  • Naples, Italy
  • Turin, Italy
  • Barcelona, Spain
  • London, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Clozapine and Second-line Antipsychotics (treatment as usual) to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Dr. Inge Winter.

Does this study involve medication?

Yes. The study involves medication, including Clozapine.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies